Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD137L-DC-EBV-VAX in Nasopharyngeal Carcinoma
NCT03282617Phase 1Unknown
- Sponsor
- National University Hospital
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD137L-DC-EBV-VAX in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by National University Hospital. Primary endpoint: Safety and tolerability and recommended dose of CD137L-DC-EBV-VAX at 3 years. Status: unknown.
02
Drugs
CD137L-DC-EBV-VAX
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03282617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282617.